14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VIVS vs ANRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas ANRO carries 34.1/100 (SELL) at $26.51 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While VIVS currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. ANRO 34.1/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10117.0% operating margin) and revenue trajectory (+0.0% vs. -51.4% YoY).
Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both VIVS (36.8/100 SELL) and ANRO (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ANRO is in a Breakdown options structure phase (RSI 52.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs ANRO. Trailing 12-month operating profitability (VIVS -10117.0% vs ANRO 0.0%) and valuation multiples (VIVS N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VIVS vs ANRO Key Questions & Quantitative Answers
As of Nov 19, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas ANRO carries 34.1/100 (SELL) at $26.51 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VIVS currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. ANRO 34.1/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10117.0% operating margin) and revenue trajectory (+0.0% vs. -51.4% YoY). Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both VIVS (36.8/100 SELL) and ANRO (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ANRO is in a Breakdown options structure phase (RSI 52.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANRO leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VIVS generates $112,000 in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.
VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus ANRO (-46.7% ROE) capital efficiency.
In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, ANRO carries 78.2% implied volatility (8th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 91% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.